Sign in
TerminatedNo phase

Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy

Key facts

Who runs it
Fidia Farmaceutici s.p.a.
Where
Italy3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
65 people enrolled
Started
14 Jun 2023
Ended
10 Mar 2025
Type of study
Interventional
Treatments tested
  • Iridium A Gel
Record updated
25 February 2026
Why it stopped
The investigation was prematurely interrupted with 65 patients enrolled due to difficulties in recruiting patients. However the results observed in the interim analysis demonstrate the performance of the investigational device.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • Have an age ≥ 18 years,
  • Have undergone the informed consent process and have signed an approved consent form
  • Are able to comprehend the full nature and the purpose of the investigation, including possible risks and side effects, and subjects able to cooperate with the Investigator and to comply with the requirements of the entire investigation (including ability to attend all the planned investigation visits according to the time limits), based on Investigator's judgement
  • Have a diagnosis of glaucoma or Ocular Hypertension (OHT). Diagnosis of glaucoma will be based on: optic disc assessment, measurement of the retinal nerve fiber layer and neuroretinal rim with optical coherence tomography (OCT); characteristic repeatable visual field defects defined as a pattern standard deviation (PSD) with P < 0.05, and/or glaucoma hemifield test (GHT) results outside normal limits. Diagnosis of OHT will be based on history of IOP (intraocular pressure) > 21 mmHg in at least two occasions and normal optic disc and Humphrey visual field test
  • Are receiving an ongoing topical therapy with two or more preserved ocular hypotensive agents (e.g. beta-blockers, alpha-agonists, carbonic anydhrase inhibitors, prostaglandins) for at least 6 months and are willing to continue these treatments at unchanged dose for the entire investigation duration
  • Have a diagnosis of moderate to severe DES performed through the following exams: slit lamp examination (SLE), tear (lacrimal) meniscus exam, Schirmer's test, Tear Film Break-Up Time (TFBUT), fluorescein staining of the cornea and conjunctiva (Oxford Staining Scheme). Please note that a diagnosis of DES may be performed at entry in the investigation
  • Have a Tear Film Break-Up Time (TFBUT) value < 7 sec
  • Have performed a Humphrey Visual Field Test in the last 4 months, if not available the test will be performed during the screening visit
  • In case of females of child-bearing potential (i.e., not permanently sterilized - post hysterectomy or tubal ligation status - or not postmenopausal), they must have a negative urine pregnancy test at T0 and use a reliable form of contraception for a least 1 month prior to T0 and throughout the investigation, according to the definition of Note 3 ofICH M3 Guideline*; Note: According to the definition of Note 3 of ICH M3 Guideline a highly effective method is defined as those which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. Highly effective birth control methods include: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence

Who cannot take part

  • Current use/use in the past 15 days of any ocular medications other than hypotensive eye drops
  • Treatment with any other therapy that, according to Investigator's judgment, could interfere with the assessment of the efficacy or incidence of adverse events
  • Use of systemic steroids or immunosuppressants
  • Contraindications to use of topical solution components used in this investigation or known allergy/hypersensitivity to any of the IRIDIUM®A gel ingredients
  • Any history or slit lamp evidence of eye surface diseases different from DES
  • History of ocular trauma or surgery in the past 12 months
  • History of cataract in the past 6 months
  • Any history of corneal refractive surgery
  • History of drug, medication or alcohol abuse or addiction
  • Best corrected visual acuity score < 20/40
  • Ischemic oculopathy
  • Systemic treatments known to affect tear secretion
  • Participation in another clinical study/investigation at the same time as the present investigation or within 30 days
  • Pregnant (positive urine pregnancy test) or breastfeeding women, or women planning to become pregnant during the investigation

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main aim of this investigation is to evaluate the effect of the preservative-free ophthalmic solution IRIDIUM® A gel on the ocular surface of patients with glaucoma or OHT and concomitant DES under multiple long-term topical hypotensive therapy for at least 6 months. The underlying assumption is that ophthalmic solutions as adjuvants for the management of IOP- or glaucoma-associated dry eye may induce a protection of the eye surface with consequent improvement of the symptoms and of the overall quality of life.

The group in the trial

  • IRIDIUM A gelTreatment being tested

    Patients will receive IRIDIUM® A gel (four boxes to be used and one spare box) and they will be instructed to bilaterally apply 1 drop per eye onto the conjunctival sac 2 times a day for 60 days (one application during the day and one before going to sleep).

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of Performance and Safety of IRIDIUM® A Gel Preservative-free Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy: a Prospective, Multicentric, Open-label Clinical Investigation.
Record updated
25 February 2026